HNRNPA2B1 and neoplasm: Targeting hnRNPA2B1 using lentivirus‐mediated shRNA or blunting m6A mRNA export using the specific inhibitor STM2457 resulted in a remarkable reduction in BCSCs stemness and tumor initiation both in vitro and in vivo, thereby enhancing the therapeutic effect of doxorubicin.